Smith Madison Shea, Clifford Antonia, Baiers Ross A, Morgan Ethan, Mustanski Brian
Institute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, 625 N Michigan Ave, Suite 1400, Chicago 60611, IL, USA.
Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA.
Int J Ment Health Addict. 2024 May 28. doi: 10.1007/s11469-024-01336-7.
Fentanyl use in the Midwest is rising, and there is data to suggest that this is a particular area of concern among sexual and gender minorities assigned male at birth (SGM-AMABs). However, little is known about intentional and non-intentional use among this population. The goal of this study was to document rates of fentanyl use and associated indicators (e.g., mode of administration) among a cohort of SGM-AMABs.
Participants ( = 924) were drawn from the RADAR cohort study of SGM-AMABs recruited from the Chicago metropolitan area. All cohort members were designated male at birth and were required to be a sexual minority (i.e., individuals who are gay, bisexual, queer; have same-sex attraction/behavior; or endorse another non-heterosexual identity), a gender minority (i.e., individuals who are transgender, nonbinary, or another non-cisgender identity), or both. All participants completed a urine drug screen as well as self-report items regarding fentanyl use, mode of administration, opioid use, injection history, and overdose via REDCap survey instrument.
Of the 924 total participants, 0.3% ( = 3) self-reported fentanyl use, and 0.5% ( = 5) tested reactive via urine drug screen for fentanyl. Other substances of use were relatively common, and self-report fentanyl use was non-overlapping with urine drug screens for fentanyl.
Although preliminary, these analyses suggest that fentanyl exposure is rare in this population. However, better screening methods to identify those who are using fentanyl by other modalities-including unintentional use-may be warranted.
芬太尼在中西部地区的使用呈上升趋势,有数据表明,这是出生时被指定为男性的性少数群体和性别少数群体(SGM-AMABs)中一个特别值得关注的领域。然而,对于该人群中芬太尼的有意和无意使用情况知之甚少。本研究的目的是记录一组SGM-AMABs中芬太尼的使用比率及相关指标(如给药方式)。
参与者(n = 924)来自于对从芝加哥大都市区招募的SGM-AMABs进行的雷达队列研究。所有队列成员出生时被指定为男性,并且必须是性少数群体(即男同性恋、双性恋、酷儿;有同性吸引/行为;或认同其他非异性恋身份)、性别少数群体(即跨性别者、非二元性别者或其他非顺性别身份),或两者皆是。所有参与者均完成了尿液药物筛查以及通过REDCap调查工具进行的关于芬太尼使用、给药方式、阿片类药物使用、注射史和过量用药的自我报告项目。
在924名参与者中,0.3%(n = 3)自我报告使用过芬太尼,0.5%(n = 5)尿液药物筛查芬太尼呈阳性。其他使用的物质相对常见,自我报告的芬太尼使用情况与芬太尼尿液药物筛查结果无重叠。
尽管这些分析是初步的,但表明该人群中芬太尼暴露情况罕见。然而,可能需要更好的筛查方法来识别那些通过其他方式(包括无意使用)使用芬太尼的人。